Trial Profile
Intravenous Remodulin (Treprostinil) as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn: A Randomized, Placebo-Controlled, Safety and Efficacy Study
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Treprostinil (Primary)
- Indications Pulmonary hypertension
- Focus Adverse reactions
- Sponsors United Therapeutics Corporation
- 06 Feb 2024 Status changed from completed to discontinued.
- 24 May 2023 Status changed from recruiting to completed.
- 12 Jul 2018 Planned End Date changed from 1 Jan 2018 to 1 Dec 2022.